We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+26.01%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.4B
AUM Growth
+$351M
Cap. Flow
+$35.9M
Cap. Flow %
0.67%
Top 10 Hldgs %
42.1%
Holding
152
New
38
Increased
33
Reduced
27
Closed
23
Avg Time Held Equity + Options
6.9 quarters
Top 10 Avg Time Held Equity + Options
4.1 quarters
Top 20 Avg Time Held Equity + Options
4.5 quarters
Avg Time Held Equity only
7.4 quarters
Top 10 Avg Time Held Equity only
4.4 quarters
Top 20 Avg Time Held Equity only
4.5 quarters

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$59.7M
2
ODTX icon
Odyssey Therapeutics
ODTX
+$52.6M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$47.6M
4
COGT icon
Cogent Biosciences
COGT
+$47.6M
5
HUM icon
Humana
HUM
+$46.7M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$54.7M
2
DHR icon
Danaher
DHR
+$50.4M
3
ELVN icon
Enliven Therapeutics
ELVN
+$50.2M
4
BSX icon
Boston Scientific
BSX
+$48.8M
5
IRON icon
Disc Medicine
IRON
+$48.8M

Sector Composition

Rank Sector Weight
1 Healthcare 97.03%
2 Miscellaneous 2.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ALHC icon
126
Alignment Healthcare
ALHC
$1.72B
– –
-791,000
Closed -$13.9M –
AMGN icon
127
Amgen
AMGN
$223B
– –
-39,900
Closed -$14M –
JBIO icon
128
Jade Biosciences
JBIO
$853M
– –
-185,011
Closed -$2.6M –
AVTX icon
129
Avalo Therapeutics
AVTX
$644M
– –
-475,165
Closed -$7.09M –
CCCC icon
130
C4 Therapeutics
CCCC
$342M
– –
-856,353
Closed -$2.25M –
CGEM icon
131
Cullinan Oncology
CGEM
$907M
– –
-243,006
Closed -$3.45M –
CMPS icon
132
Compass Pathways
CMPS
$1.54B
– –
-1,150,646
Closed -$6.36M –
DHR icon
133
Danaher
DHR
$157B
– –
-265,800
Closed -$50.4M –
ESPR icon
134
DELISTED
Esperion Therapeutics
ESPR
– –
-10,570,300
Closed -$29M –
GILD icon
135
Gilead Sciences
GILD
$183B
– –
-59,600
Closed -$8.31M –
HRTX icon
136
Heron Therapeutics
HRTX
$74.2M
– –
-9,816,940
Closed -$7.85M –
KALV icon
137
DELISTED
KalVista Pharmaceuticals
KALV
– –
-94,400
Closed -$1.9M –
MDXH icon
138
CALL
MDxHealth
MDXH
$63M
– –
-124,306,000
Closed -$286M –
PFE icon
139
Pfizer
PFE
$162B
– –
-1,946,500
Closed -$54.7M –
QGEN icon
140
CALL
Qiagen
QGEN
$9.38B
– –
-250,000
Closed -$10M –
RCEL icon
141
CALL
Avita Medical
RCEL
$413M
– –
-40,966,100
Closed -$154M –
RCEL icon
142
Avita Medical
RCEL
$413M
– –
-544,895
Closed -$42.5M –
REGN icon
143
Regeneron Pharmaceuticals
REGN
$77.5B
– –
-14,700
Closed -$11.4M –
SLNO icon
144
CALL
DELISTED
Soleno Therapeutics
SLNO
– –
-100,000
Closed -$3.35M –
VTGN icon
145
VistaGen Therapeutics
VTGN
$9.53M
– –
-3,060,000
Closed -$1.75M –
BTSG icon
146
BrightSpring Health Services
BTSG
$12.4B
– –
-497,800
Closed -$21.2M –
CARL icon
147
Carlsmed
CARL
$395M
– –
-1,252,600
Closed -$11.3M –
2 3 4 5
6

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2026 Portfolio in Review

As of Q2 2026, OrbiMed held 152 positions worth $5.4B, up 7% from $5.05B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

OrbiMed's Q2 2026 filing shows 38 new, 33 increased, 27 reduced and 23 closed positions. Its largest new stake was UnitedHealth: 161,100 shares worth $67M. The largest sale was Pfizer, an estimated $54.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier, followed by Miscellaneous.

  • OrbiMed's largest Q2 2026 buy was UnitedHealth: 161,100 shares worth $67M.
  • OrbiMed added most to Cogent Biosciences in Q2 2026, an estimated $47.6M increase.
  • OrbiMed's biggest Q2 2026 reduction was Enliven Therapeutics, cutting an estimated $50.2M.
  • OrbiMed fully exited Pfizer in Q2 2026, selling an estimated $54.7M.
  • OrbiMed's ten largest holdings make up 42% of its $5.4B portfolio in Q2 2026.
  • OrbiMed opened 38 new positions and closed 23 in Q2 2026.
  • OrbiMed's portfolio value rose 7% quarter-over-quarter to $5.4B.

Based on OrbiMed's 13F filing for Q2 2026, filed 14 Aug 2026.